Suchergebnisse - "Kates, R E"

PubPharm (111)

1

Significantly longer time to deterioration of quality of life due to CANKADO PRO-React eHealth support in HR+ HER2- metastatic breast cancer patients receiving palbociclib and endocrine therapy : primary outcome analysis of the multicenter randomized AGO-B WSG PreCycle trial

enthalten in: Annals of oncology : official journal of the European Society for Medical Oncology | 2023

von Harbeck, N. | Fasching, P. | Wuerstlein, R. | +77

CommentIn: Ann Oncol. 2023 Aug;34(8):635-637. - PMID 37423674

2

Final analysis of the prospective WSG-AGO EC-Doc versus FEC phase III trial in intermediate-risk (pN1) early breast cancer : efficacy and predictive value of Ki67 expression

enthalten in: Annals of oncology : official journal of the European Society for Medical Oncology | 2017

von Nitz, U. | Gluz, O. | Huober, J. | +22

ErratumFor: Ann Oncol. 2014 Aug;25(8):1551-7. - PMID 24827128

3

The West German Study Group Breast Cancer Intrinsic Subtype study : a prospective multicenter decision impact study utilizing the Prosigna assay for adjuvant treatment decision-making in estrogen-receptor-positive, HER2-negative early-stage breast cancer

enthalten in: Current medical research and opinion | 2016

von Wuerstlein, R. | Sotlar, K. | Gluz, O. | +17

4

Comparison of prognostic and predictive impact of genomic or central grade and immunohistochemical subtypes or IHC4 in HR+/HER2- early breast cancer : WSG-AGO EC-Doc Trial

enthalten in: Annals of oncology : official journal of the European Society for Medical Oncology | 2016

von Gluz, O. | Liedtke, C. | Huober, J. | +17

5

The West German Study Group Breast Cancer Intrinsic Subtype study: a prospective multicenter decision impact study utilizing the Prosigna assay for adjuvant treatment decision-making in estrogen-receptor-positive, HER2-negative early-stage breast cancer

enthalten in: Current medical research and opinion | 2016

von Wuerstlein, R. | Sotlar, K. | Gluz, O. | +17

6

Comparison of prognostic and predictive impact of genomic or central grade and immunohistochemical subtypes or IHC4 in HR+/HER2- early breast cancer: WSG-AGO EC-Doc Trial

enthalten in: Annals of oncology | 2016

von Gluz, O. | Liedtke, C. | Huober, J. | +17

7

The West German Study Group Breast Cancer Intrinsic Subtype study: a prospective multicenter decision impact study utilizing the Prosigna assay for adjuvant treatment decision-making in estrogen-receptor-positive, HER2-negative early-stage breast cancer

enthalten in: Current medical research and opinion | 2016

von Wuerstlein, R. | Sotlar, K. | Gluz, O. | +17

8

P231 Luminal subtypes vs. early Ki-67 response and Oncotype DX® in early breast cancer: WSG-ADAPT study

enthalten in: The breast | 2015

von Gluz, O. | Nitz, U. | Christgen, M. | +7

9

Final analysis of the prospective WSG-AGO EC-Doc versus FEC phase III trial in intermediate-risk (pN1) early breast cancer : efficacy and predictive value of Ki67 expression

enthalten in: Annals of oncology : official journal of the European Society for Medical Oncology | 2014

von Nitz, U. | Gluz, O. | Huober, J. | +22

ErratumIn: Ann Oncol. 2017 Nov 1;28(11):2899. - PMID 27634692

10

Final results from the prospective phase III WSG-ARA trial : impact of adjuvant darbepoetin alfa on event-free survival in early breast cancer

enthalten in: Annals of oncology : official journal of the European Society for Medical Oncology | 2014

von Nitz, U. | Gluz, O. | Zuna, I. | +13

1
2
3
4
5
6
7
8
9
10
11
Nächster »
[12]